Vamsidhar Velcheti, MD

Articles by Vamsidhar Velcheti, MD

Cancer Network Faceoff: Conclusion of the Event and Presentation of Awards

ByDeborah Doroshow, MD,Neel Chudgar, MD,Vamsidhar Velcheti, MD,Daniel R. Gomez, MD,Jamie E Chaft, MD,Fred R. Hirsch, MD, PhD,Mark G. Kris, MD

December 28th 2023

Conclusion of the discussion and award presentation.

Optimal Approach for PD-L1 >50%

ByDeborah Doroshow, MD,Neel Chudgar, MD,Vamsidhar Velcheti, MD,Daniel R. Gomez, MD,Jamie E Chaft, MD,Fred R. Hirsch, MD, PhD,Mark G. Kris, MD

December 21st 2023

Discussion regarding immunotherapy alone or in combination with chemotherapy for patients with NSCLC that are PD-L1 >50%.

Treatment for Borderline Resectable Patients With NSCLC

ByDeborah Doroshow, MD,Neel Chudgar, MD,Vamsidhar Velcheti, MD,Daniel R. Gomez, MD,Jamie E Chaft, MD,Fred R. Hirsch, MD, PhD,Mark G. Kris, MD

December 21st 2023

Discussion on the treatment for borderline resectable patients with NSCLC.

Will Combination Therapies Replace Osimertinib Monotherapy as Standard-of-Care in Frontline EGFR-Mutant Advanced NSCLC?

ByDeborah Doroshow, MD,Neel Chudgar, MD,Vamsidhar Velcheti, MD,Daniel R. Gomez, MD,Jamie E Chaft, MD,Fred R. Hirsch, MD, PhD,Mark G. Kris, MD

December 14th 2023

Osimertinib monotherapy as the standard of treatment for frontline EGFR mutant advanced NSCLC will be replaced by combination therapies.

Adjuvant Osimertinib for Resected EGFR Mutated Stage IB-IIIA Non-Small Cell Lung Cancer

ByDeborah Doroshow, MD,Neel Chudgar, MD,Vamsidhar Velcheti, MD,Daniel R. Gomez, MD,Jamie E Chaft, MD,Fred R. Hirsch, MD, PhD,Mark G. Kris, MD

December 14th 2023

EGFR-mutated stage IB-IIIA non-small cell lung carcinoma that has been removed and treated with adjuvant osimertinib.

Brigatinib Versus Crizotinib in ALK inhibitor-Naïve Advanced ALK-Positive NSCLC: Results of Phase 3 ALTA-1L Trial

ByDeborah Doroshow, MD,Neel Chudgar, MD,Vamsidhar Velcheti, MD,Daniel R. Gomez, MD,Jamie E Chaft, MD,Fred R. Hirsch, MD, PhD,Mark G. Kris, MD

December 7th 2023

Results of phase 3 ALTA-1L study comparing crizotinib with Brigatinib in advanced ALK-positive non-small cell lung cancer

Introduction of the Debate Between Jets v. Giants

ByDeborah Doroshow, MD,Neel Chudgar, MD,Vamsidhar Velcheti, MD,Daniel R. Gomez, MD,Jamie E Chaft, MD,Fred R. Hirsch, MD, PhD,Mark G. Kris, MD

December 7th 2023

An outline of the debate, the speakers, and the basic guidelines to support the program.

Tools, Biomarkers Needed to Identify Immune-Related Toxicities

ByVamsidhar Velcheti, MD

September 6th 2017

This video reviews the need for biomarkers and tools that could identify those at high risk of immune-related toxicities among patients undergoing immunotherapy treatment.

Latest Updated Articles

Tools, Biomarkers Needed to Identify Immune-Related Toxicities
Published: September 6th 2017 | Updated:

Vamsidhar Velcheti, MD

Articles by Vamsidhar Velcheti, MD

Cancer Network Faceoff: Conclusion of the Event and Presentation of Awards

Optimal Approach for PD-L1 >50%

Treatment for Borderline Resectable Patients With NSCLC

Will Combination Therapies Replace Osimertinib Monotherapy as Standard-of-Care in Frontline EGFR-Mutant Advanced NSCLC?

Adjuvant Osimertinib for Resected EGFR Mutated Stage IB-IIIA Non-Small Cell Lung Cancer

Brigatinib Versus Crizotinib in ALK inhibitor-Naïve Advanced ALK-Positive NSCLC: Results of Phase 3 ALTA-1L Trial

Introduction of the Debate Between Jets v. Giants

Tools, Biomarkers Needed to Identify Immune-Related Toxicities

Latest Updated Articles

Trending on CancerNetwork

Frontline Alectinib Upholds OS Benefit in Advanced ALK+ NSCLC

Episode 16: Anticipated ESMO 2025 Data That May Change GU Oncology

Perioperative Durvalumab/NAT Chemo Does Not Improve HRQOL in MIBC

Osimertinib/Chemo Yields OS Improvement Across Subgroups of EGFR+ NSCLC

Exploring the ESMO 2025 Presentations That May Shift GU Oncology